Dr Borad on the Initial Efficacy of RLY-4008 in FGFR2 Fusion

Mitesh Borad, MD, key findings from the phase 1/2 ReFocus trial in FGFR2-altered cholangiocarcinoma.

Related Keywords

, Mayo Clinic Comprehensive Cancer Center , Department Of Medical Oncology , Medical Oncology , Onclive Tv , Mayo Clinic , Rly 4008 , Fgfr2 Fusion , Cholangiocarcinoma ,